THERACLION |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.37 EUR | +6.02% |
|
+2.78% | -4.64% |
| Sales 2021 | 1.48M 1.59M | Sales 2022 | 1.24M 1.33M | Capitalization | 26.15M 28.14M |
|---|---|---|---|---|---|
| Net income 2021 | -3M -3.23M | Net income 2022 | -4M -4.3M | EV / Sales 2021 | 24.8 x |
| Net Debt 2021 | 6.99M 7.52M | Net Debt 2022 | 6.52M 7.02M | EV / Sales 2022 | 26.4 x |
| P/E ratio 2021 |
-7.93
x | P/E ratio 2022 |
-5.35
x | Employees | 30 |
| Yield 2021 * |
-
| Yield 2022 |
-
| Free-Float | 71.21% |
More Fundamentals
* Assessed data
More news
More press releases
More news
| 1 day | +6.02% | ||
| 1 week | +2.78% | ||
| Current month | +0.82% | ||
| 1 month | +1.09% | ||
| 3 months | -28.57% | ||
| 6 months | -26.29% | ||
| Current year | -4.64% |
1 week
0.34
0.39
1 month
0.340.39
Current year
0.310.68
1 year
0.300.85
3 years
0.302.28
5 years
0.302.76
10 years
0.3014.00
| Managers | Title | Age | Since |
|---|---|---|---|
Martin Deterre
CEO | Chief Executive Officer | - | 19-12-31 |
Laurence Géricot
DFI | Director of Finance/CFO | - | - |
Gaylord Tallec
COO | Chief Operating Officer | - | - |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Ari Kellen
BRD | Director/Board Member | - | 19-02-12 |
Renaud Saleur
BRD | Director/Board Member | - | 18-01-31 |
Yann Duchesne
CHM | Chairman | 67 | 22-01-23 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-03 | 0.37 | +6.02% | 7,215 |
| 24-05-02 | 0.349 | -4.90% | 42,673 |
| 24-04-30 | 0.367 | -2.13% | 6,569 |
| 24-04-29 | 0.375 | +4.17% | 165,793 |
| 24-04-26 | 0.36 | -1.10% | 7,377 |
Real-time Euronext Paris, May 03, 2024 at 08:10 am EDT
More quotes
Theraclion specializes in developping, manufacturing and marketing echotherapy equipment associating therapy with focused ultrasound (HIFU) and monitoring by ultrasound. The company provides Echopulse, a device for non-invasive and outpatient treatment of mammary fibroadenoma and thyroid nodules.Net sales break down by activity as follows:
- sale of equipment (61.8%);
- sale of consumables (29%);
- provision of after-sales services (9.2%).
Export accounts for 99.7% of net sales.
Calendar
2024-09-18
- Q2 2024 Earnings Release (Projected)
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -4.64% | 18.07M | |
| +7.84% | 218B | |
| +7.35% | 184B | |
| +13.04% | 135B | |
| +26.03% | 107B | |
| -1.33% | 62.38B | |
| +11.80% | 51.37B | |
| +4.81% | 50.9B | |
| +0.30% | 40.87B | |
| +2.78% | 36.28B |
- Stock Market
- Equities
- ALTHE Stock
